Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $30,244.20 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 1,596 shares of the stock in a transaction on Friday, March 20th. The shares were sold at an average price of $18.95, for a total value of $30,244.20. Following the transaction, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at approximately $6,431,478.40. The trade was a 0.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.84, for a total value of $122,441.16.
• On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.78, for a total value of $129,675.90.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total value of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total transaction of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Trading Down 2.0%

Shares of NASDAQ BCAX opened at $18.41 on Monday. The firm has a 50-day moving average of $16.98 and a two-hundred day moving average of $16.34. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -8.22 and a beta of -0.78. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $20.25.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP lifted its position in Bicara Therapeutics by 2.0% during the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after acquiring an additional 100,000 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its position in shares of Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after purchasing an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $44,484,000. Vanguard Group Inc. increased its stake in shares of Bicara Therapeutics by 9.8% in the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after purchasing an additional 195,667 shares during the period. Finally, State Street Corp increased its stake in shares of Bicara Therapeutics by 179.5% in the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after purchasing an additional 1,059,260 shares during the period.

Analyst Ratings Changes

BCAX has been the subject of several recent analyst reports. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Citigroup initiated coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating on the stock. Citizens Jmp initiated coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Finally, Mizuho upgraded Bicara Therapeutics to a “hold” rating in a research report on Thursday, December 18th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.25.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.